Close Menu

BRAF Biomarkers

News and reporting on BRAF biomarkers.

The Jerusalem-based drug developer is studying PLX8394 in patients with BRAF V600-mutated gliomas and solid tumors with non-V600 mutations. 

Researchers showed that ctDNA levels predicted who would respond to first-line immune checkpoint inhibition but were not useful in second-line therapy.

The ulixertinib program is open to adult and adolescent cancer patients who have exhausted other treatment options and who have MAPK pathway alterations.

The firm is exploring whether the regimen may work for subgroups of patients with high TMB based on promising signals from the current failed analysis.

The company will use the proceeds to advance its lead BRAF inhibitor, PLX-8394, and develop new precision drugs using its FACT platform.

Kinnate aims to advance its lead candidates into clinical trials next year and collaborate with investigators at precision cancer centers on future research projects.

The first prospective study of BRAF-mutated cholangiocarcinoma showed a 51 percent response rate among patients treated with Novartis' Tafinlar and Mekinist.

The approval is based on the results from the Phase III IMspire150 study, in which patients treated with the three-drug combination had an improvement in progression-free survival.

Through the partnership, Strata will use its next-generation sequencing test to identify advanced cancer patients with mutations in the MAPK signaling pathway.

The study will evaluate the safety, tolerability and clinical activity of JSI-1187 in patients with relapsed, refractory solid tumors containing mutations in the MAPK pathway.

Pages